Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | PTGER4 | P35408 | 3/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.80 |
| ▸ | PKM | P14618 | 1/20 | 0.80 |
| ▸ | CRHBP | P24387 | 1/20 | 0.80 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.80 |
| ▸ | HCAR3 | P49019 | 5/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15774665 | 0.93 | MAPT (0.87) | MAPTALDH1A1PTGER4RAB9ANPC1 | |
| SCHEMBL2252228 | 0.90 | MAPT (0.82) | MAPTALDH1A1PTGER4RAB9ANPC1 | |
| SCHEMBL22382354 | 0.86 | MAPT (0.81) | MAPTALDH1A1PTGER4RAB9ANPC1 | |
| SCHEMBL9043097 | 0.86 | MAPT (0.84) | MAPTALDH1A1PTGER4RAB9ANPC1 | |
| SCHEMBL6043949 | 0.85 | HCAR3 (1.00) | MAPTALDH1A1PTGER4RAB9ANPC1 | |
| SCHEMBL15321333 | 0.85 | MAPT (0.82) | MAPTALDH1A1PTGER4RAB9ANPC1 | |
| SCHEMBL22382490 | 0.85 | MAPT (0.78) | MAPTALDH1A1PTGER4RAB9ANPC1 | |
| SCHEMBL20797593 | 0.84 | MAPT (0.73) | MAPTALDH1A1PTGER4RAB9ANPC1 | |
| SCHEMBL2552519 | 0.84 | HCAR3 (0.79) | MAPTALDH1A1PTGER4RAB9ANPC1 | |
| SCHEMBL22382547 | 0.84 | MAPT (0.77) | MAPTALDH1A1PTGER4RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240409533-A1 | HMOX1 INDUCERS | Astellas Engineered Small Molecules US, Incorporated | 2024-12-12 | — | — | US | disclosed |
| CN-113874074-B | HMOX1 inducers | 米托布里奇公司 | 2024-11-01 | — | — | CN | disclosed |
| US-12071433-B2 | HMOX1 inducers | Astellas Engineered Small Molecules US, Incorporated (US) | 2024-08-27 | — | — | US | disclosed |
| US-20240051952-A1 | HMOX1 INDUCERS | Astellas Engineered Small Molecules US, Incorporated | 2024-02-15 | — | — | US | disclosed |
| US-20220177460-A1 | HMOX1 INDUCERS | Astellas Engineered Small Molecules US, Incorporated | 2022-06-09 | — | — | US | disclosed |
| EP-3952990-A1 | HMOX1 INDUCERS | Mitobridge, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| CN-113874074-A | HMOX1 inducers | 米托布里奇公司 | 2021-12-31 | — | — | CN | disclosed |
| WO-2020210339-A1 | HMOX1 INDUCERS | MITOBRIDGE, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| US-10766888-B1 | HMOX1 inducers | MITOBRIDGE INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10730856-B2 | Benzimidazole derivatives as EP4 ligands | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-08-04 | — | — | US | disclosed |
| US-20160214977-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | BAYER ANIMAL HEALTH GMBH (DE) | 2016-07-28 | — | — | US | disclosed |
| CN-105814038-A | Benzimidazole derivatives as EP4 ligands | 拜耳医药股份公司 | 2016-07-27 | — | — | CN | disclosed |
| EP-2928884-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | Bayer Pharma Aktiengesellschaft (DE) | 2015-10-14 | — | — | EP | disclosed |
| WO-2015091475-A1 | BENZIMIDAZOLE DERIVATIVES AS EP4-LIGANDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015091475-A1 | BENZIMIDAZOLE DERIVATIVES AS EP4-LIGANDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | WO | disclosed |
| US-8916599-B2 | 1H-benz imidazole-5-carboxamides as anti-inflammatory agents | OREXO AB (SE) | 2014-12-23 | — | — | US | disclosed |
| WO-2014086739-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-06-12 | — | — | WO | disclosed |
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| EP-2334652-A1 | 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | Boehringer Ingelheim International GmbH (DE) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010034796-A1 | 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10766888-B1 | HMOX1 inducers | HMOX1, HMOX2, HMBS | MAPT 3846/4885ALDH1A1 332/4885PTGER4 413/4885 |
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | MAPRE2, MAPRE1, H1-4 | MAPT 480/4885ALDH1A1 1202/4885PTGER4 232/4885 |
| US-20240409533-A1 | HMOX1 INDUCERS | HMOX1, HMOX2, HMBS | MAPT 3846/4885ALDH1A1 332/4885PTGER4 413/4885 |
| US-20160214977-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | PTGER4, PTGER1, PTGER2 | MAPT 4657/4885ALDH1A1 560/4885PTGER4 1/4885 |
| US-12071433-B2 | HMOX1 inducers | HMOX1, HMOX2, HMBS | MAPT 3756/4885ALDH1A1 223/4885PTGER4 342/4885 |
| US-20240051952-A1 | HMOX1 INDUCERS | HMOX1, HMOX2, QSOX1 | MAPT 3238/4885ALDH1A1 266/4885PTGER4 743/4885 |
| US-20220177460-A1 | HMOX1 INDUCERS | HMOX1, HMOX2, HMBS | MAPT 3756/4885ALDH1A1 223/4885PTGER4 342/4885 |
| US-10730856-B2 | Benzimidazole derivatives as EP4 ligands | PTGER4, PTGER1, PTGER2 | MAPT 4684/4885ALDH1A1 382/4885PTGER4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.